“…Therefore, the prevalence of subclinical and/or overt hypothyroidism was 34.8%, 10.4%, or 5.7% according to the reference range suggested by the 2011 ATA guideline, the manufacturer's reference, and the present study, respectively (shown in Fig. 3 of Castillo et al [ 12 ]). This discrepancy means that the number of pregnant women to be treated by levothyroxine varies significantly according to the choice of the TSH reference range.…”